G
Gisela Barbany
Researcher at Karolinska Institutet
Publications - 92
Citations - 5335
Gisela Barbany is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Minimal residual disease & Leukemia. The author has an hindex of 28, co-authored 79 publications receiving 4923 citations. Previous affiliations of Gisela Barbany include Karolinska University Hospital & Uppsala University.
Papers
More filters
Journal ArticleDOI
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
Jean Gabert,Emmanuel Beillard,V H J van der Velden,Wanli Bi,David Grimwade,Niels Pallisgaard,Gisela Barbany,Giovanni Cazzaniga,Jean Michel Cayuela,Hélène Cavé,Fabrizio Pane,J. L. E. Aerts,D De Micheli,X Thirion,V Pradel,Marcos González,Susanne Viehmann,Maria Malec,Giuseppe Saglio,J. J. M. Van Dongen +19 more
TL;DR: The development of standardized protocols for RQ-PCR analysis of FG transcripts provides a milestone for molecular determination of MRD levels and is likely to prove invaluable to the management of patients entered into multicenter therapeutic trials.
Journal ArticleDOI
Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve
Hiroshi Funakoshi,Jonas Frisén,Gisela Barbany,Tõnis Timmusk,O Zachrisson,Valerie M. K. Verge,Håkan Persson +6 more
TL;DR: Results show that expression of mRNAs for neurotrophins and their Trk receptors is differentially regulated after a peripheral nerve injury and a model is presented for how the different neurotrophin could cooperate to promote regeneration of injured peripheral nerves.
Journal ArticleDOI
Disruption of the low affinity receptor-binding site in NGF allows neuronal survival and differentiation by binding to the trk gene product.
Carlos F. Ibáñez,Ted Ebendal,Gisela Barbany,Judith Murray-Rust,Tom L. Blundell,Håkan Persson +5 more
TL;DR: It is shown that Lys-32, Lys-34, and Lys-95 form a positively charged interface involved in binding to p75NGFR, demonstrating a functional dissociation between the two NGF receptors.
Journal ArticleDOI
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Matthew S. Zabriskie,Christopher A. Eide,Christopher A. Eide,Srinivas K. Tantravahi,Nadeem A. Vellore,Johanna Estrada,Franck E. Nicolini,Hanna Jean Khoury,Richard A. Larson,Marina Konopleva,Jorge E. Cortes,Hagop M. Kantarjian,Elias J. Jabbour,Steven M. Kornblau,Jeffrey H. Lipton,Delphine Rea,Leif Stenke,Gisela Barbany,Thoralf Lange,Juan Carlos Hernández-Boluda,Gert J. Ossenkoppele,Richard D. Press,Charles Chuah,Stuart L. Goldberg,Meir Wetzler,François Xavier Mahon,Gabriel Etienne,Michele Baccarani,Simona Soverini,Gianantonio Rosti,Philippe Rousselot,Ran Friedman,Marie Deininger,Kimberly R. Reynolds,William L. Heaton,Anna M. Eiring,Anthony D. Pomicter,Jamshid S. Khorashad,Todd W. Kelley,Riccardo Baron,Brian J. Druker,Brian J. Druker,Michael W. Deininger,Thomas O'Hare +43 more
TL;DR: These findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome, and in vitro resistance profiling was predictive of treatment outcomes in Ph(+) leukemia patients.
Journal ArticleDOI
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
Nicholas C.P. Cross,Helen E. White,Dolors Colomer,Hans Ehrencrona,Letizia Foroni,Enrico Gottardi,Thoralf Lange,Thomas Lion,K Machova Polakova,Stéphanie Dulucq,Giovanni Martinelli,E. Oppliger Leibundgut,Niels Pallisgaard,Gisela Barbany,Tomasz Sacha,Rodica Talmaci,Barbara Izzo,Giuseppe Saglio,Fabrizio Pane,Martin C. Müller,Andreas Hochhaus +20 more
TL;DR: Detailed laboratory recommendations are presented to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.